Skip to main content
PLOS One logoLink to PLOS One
. 2023 Apr 4;18(4):e0283122. doi: 10.1371/journal.pone.0283122

Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease—Outcome of the Screening Visual Complaints questionnaire

Iris van der Lijn 1,2,*, Gera A de Haan 1,2, Fleur E van der Feen 1,2, Famke Huizinga 1,3, Catharina Stellingwerf 2, Teus van Laar 4, Joost Heutink 1,2
Editor: Thiago P Fernandes5
PMCID: PMC10072373  PMID: 37014842

Abstract

Introduction

Visual complaints can have a vast impact on the quality of life of people with Parkinson’s disease (PD). In clinical practice however, visual complaints often remain undetected. A better understanding of visual complaints is necessary to optimize care for people with PD and visual complaints. This study aims at determining the prevalence of visual complaints experienced by a large outpatient cohort of people with PD compared to a control group. In addition, relations between visual complaints and demographic and disease-related variables are investigated.

Methods

The Screening Visual Complaints questionnaire (SVCq) screened for 19 visual complaints in a cohort of people with idiopathic PD (n = 581) and an age-matched control group without PD (n = 583).

Results

People with PD experienced significantly more complaints than controls, and a greater impact of visual complaints on their daily lives. Complaints that were most common (‘often/always’) were unclear vision (21.7%), difficulty reading (21.6%), trouble focusing (17.1%), and blinded by bright light (16.8%). Largest differences with controls were found for double vision, needing more time to see and having trouble with traffic participation due to visual complaints. Age, disease duration, disease severity, and the amount of antiparkinsonian medication related positively to the prevalence and severity of visual complaints.

Conclusion

Visual complaints are highly prevalent and occur in great variety in people with PD. These complaints progress with the disease and have a large impact on the daily lives of these people. Standardized questioning is advised for timely recognition and treatment of these complaints.

Introduction

Visual problems are increasingly recognized as part of the symptomatology of Parkinson’s disease (PD) [1]. The presence of visual problems may have a vast impact on the quality of life of people with PD [2,3]. Vision is essential for the performance of most daily life activities, e.g., reading or mobility-related tasks such as driving. Moreover, people with PD may need to rely on vision even more than healthy individuals do, to compensate for the loss in motor function [4]. Loss of visual function may thus increase fall risk and decrease independence in daily life [35].

Timely recognition and treatment of visual complaints is therefore of high importance. As self-reported complaints are an indication of the difficulties a person encounters in daily life, asking about them is an essential complement to screening for possible ophthalmological conditions (OCs) or visual function disorders. It ensures that treatment is focused on the person’s priorities, regardless of the cause [6,7].

However, in scientific literature and clinical practice, visual complaints of people with PD are often underreported and unrecognized [4,8]. A recent systematic review on visual complaints in people with PD indicated that literature on this topic is still scarce [2]. Most studies had small sample sizes and examined only one or few visual complaints. Literature did indicate that visual complaints occur in great variety in people with PD. Complaints were described in terms of functions (e.g., blurred vision, double vision, increased sensitivity to light or changes in contrast sensitivity) or activities (e.g., difficulty reading, reaching, or driving). Most studies included in this review showed that visual complaints were more prevalent in people with PD compared to people without PD, and that the presence of visual complaints was related to a longer disease duration, higher disease severity, and off-state.

In clinical practice, visual complaints often go undetected for a number of reasons. People with PD might not report their visual problems because, e.g., a) other symptoms may be more prominent, b) there is limited time during health care visits to discuss all problems, c) people tend to find it hard to specify their visual complaints [9], d) people might not connect visual problems to PD, since this connection is often unknown [3] and visual problems might present even before motor symptoms arise [10], and e) in most cases no structured questions are asked by the clinician, resulting in a full reliance on the person’s (possibly decreased) self-initiated declaration [11]. A better understanding of PD-related visual complaints is important to guide care, thereby optimizing the safety and quality of life of people with PD [3]. This can be achieved by studying a diversity of function and activity related visual complaints in a large sample, which has not been done before. The Screening Visual Complaints questionnaire (SVCq) was developed for this purpose and validated in a community sample (individuals without severe ophthalmological, neurological and psychiatric disorders) [12]. To validate the SVCq in a clinical sample, our previous study examined the factor structure of the questionnaire, based on data from a large cohort of people with PD and an age-matched control group randomly selected from the aforementioned community sample [13]. A five-factor model (i.e., five subscales) was identified for good understanding of the distribution of complaints in people with PD. However, to provide a straightforward indication of the presence of visual complaints or to identify specific targets for treatment, the previous study indicated that in addition to subscale scores, total scores or scores on individual items might also be useful [13]. The current study therefore uses these scores to investigate the prevalence of self-reported visual complaints in people with PD, compared to a control group, using the validated SVCq on the same samples as the previous study [13]. In addition, the relationship between these complaints and various demographic and disease-related characteristics and the presence of an identified OC will be explored.

Method

This study used a large dataset of people with PD and controls, which is the same dataset as used in the study regarding the factor structure of the SVCq [13].

Participants

All Dutch speaking people with PD who visited the Parkinson Expertise Center in Groningen, the Netherlands, were eligible for participation in the study. PD diagnosis was based on the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria [14]. Data of a comparison group without PD was collected by Huizinga et al. (2020) [12]. This group was selected to be representative of the community sample, without severe self-reported neurological, ophthalmological, and psychiatric conditions; mild conditions were allowed in this group (see notes e–f below Table 1). See our previous study for more details on inclusion and participants [13].

Table 1. Demographics and disease characteristics of people with PD and age-matched controls.

People with PD Controls
N 581 583
Sex (n, % female) 227, 39.1% 214, 36.7%
Age (years; M ± SD) 69.25 ± 9.01 69.17 ± 8.99
Educationa (n, %)
Low 100, 17.2% 132, 22.7%
Medium 211, 36.3% 146, 25.1%
High 265, 45.6% 303, 52.2%
Disease duration (years; M ± SD) 7.96 ± 6.59 -
H&Y stage (n, %)
1 125, 21.5% -
2 218, 37.5% -
3 101, 17.4% -
≥4 49, 8.4% -
Missing 88, 15.2% -
Presence of DBS (n, %) 81, 13.9% -
LEDDb (mg; M ± SD); missing (n, %) 907.75 ± 592.01; 5, 0.9% -
Levodopa (n, %) 561, 97.4%
Dopamine agonists (n, %) 264, 45.8%
Monoamine oxidase-B inhibitors (n, %) 28, 4.9%
No antiparkinsonian medication (n, %) 6, 1.0%
Visited ophthalmologist (self-reported) 253, 43.5% 243, 41.7%
Presence of severe neurological condition (n, %)c 51, 8.8%d -
Presence of severe psychiatric condition (n, %)c 13, 2.2%e -
Presence of any ophthalmological condition (n, %)f
Yes 203, 34.9% 127, 21.8%
No 351, 60.4% 407, 69.8%
Unclear 27, 4.7% 49, 8.4%

Note: This table is similar to the one describing the same population in a previous publication [13]. DBS = Deep Brain Stimulation; H&Y = Hoehn and Yahr staging [15]; LEDD = Levodopa equivalent daily dose; M = mean; mg = milligram; n = number; PD = Parkinson’s disease; SD = standard deviation.

a Categorization based on the International Standard Classification of Education (ISCED) [16].

b LEDD calculated according to protocol of Tomlinson et al. (2010) [17].

c Severe conditions that were used as an exclusion criterion for controls and might influence vision.

d Cerebrovascular accident (n = 16), transient ischemic attack (n = 15), epilepsy (n = 10), basilar skull fracture/traumatic injury (n = 6), thalamatomy (n = 4), encephalopathy (n = 2), brain tumor (n = 2), neuroborreliosis (n = 1), cavernoma (n = 1), and pituitary tumor resection (n = 1).

e Schizophrenia/psychosis (n = 13).

f See S1 Table.

Materials

Screening visual complaints questionnaire

The SVCq screens for visual complaints in people with neurodegenerative diseases [12]. The first item of the SVCq inquires individuals whether they experienced any visual complaints in the past couple of weeks, and if so, what kind of visual complaints they have experienced. This open-ended question allows people to report spontaneous complaints. This question is followed by 19 structured items, each describing a visual complaint. Individuals indicated the frequency in which they experienced each complaint (‘never/hardly’, ‘sometimes’, ‘often/always’). In addition, to measure the impact of the visual complaints on their daily lives, individuals indicated to what extent the complaints limited them in their daily lives (on a scale from 0 (not limited at all) to 10 (severely limited); i.e., ‘impact on daily life score’). In addition to the visual complaints, individuals were asked to provide demographics (i.e., year of birth, age, gender, and level of education) and any present OC. In individuals without severe ophthalmological, neurological and psychiatric disorders, the SVCq has shown a good internal consistency (⍺ = 0.85) and test-retest reliability (ICC = 0.82) [12]. In addition, a clear and clinically relevant factor structure has been demonstrated in people with PD; five subscales were identified. Together with the total score, the impact on daily live score, and scores on individual items of the questionnaire, the five subscales contribute to a full understanding of a person’s complaints, providing a solid basis for individualized visual care [13].

Data from medical files

Disease-related data were recorded from the medical files of each individual, including disease type (PD or another related disorder), duration (time since diagnosis) and Hoehn and Yahr stage (H&Y) [15] for disease severity. Furthermore, data on current medication, neurological, ophthalmological, or psychiatric comorbidity, as well as a history of Deep Brain Stimulation (DBS) were collected.

Procedure

All Dutch speaking patients visiting the Parkinson Expertise Center in Groningen between May 1st 2019 and February 3rd 2021 were asked to fill out the SVCq. The SVCq is freely available for use in clinical practice (see supplementary material or the original publication [12]: for the Dutch version, see S2 Table or https://doi.org/10.1371/journal.pone.0232232.s001 [12]; for the English version, see S3 Table or https://doi.org/10.1371/journal.pone.0232232.s002 [12]). They were asked to complete the questionnaire in the waiting room. Individuals who were not able to complete the questionnaire on location were provided with a pre-paid return envelope to complete the questionnaire at home. Another option was to complete the SVCq online via Qualtrics (https://www.qualtrics.com). Due to COVID restrictions, from March 2020 on, SVCq distribution was done by sending people questionnaires to fill out at home.

In addition to the questionnaire, people could indicate whether they were interested to receive advice or rehabilitation for their visual complaints.

All individuals signed informed consent for providing pseudo-anonymized questionnaire data and several disease-related characteristics from their medical charts for research. According to the Medical Ethics Committee of the University Medical Center Groningen, no further ethical approval from the committee was required as all data were collected from standard care.

Data of controls were collected through Panel Inzicht, an online research panel in the Netherlands. A small financial reward was provided to individuals for filling out the online version of the SVCq. All participants provided written informed consent and ethical approval was provided by the Ethical Committee Psychology of the University of Groningen. See previous studies for more details on data collection and procedures [12,13].

Data-analysis

All analyses were performed with SPSS 26 [18]. Data used in this study are available upon request via DataverseNL (https://doi.org/10.34894/ODVGUV).

Matching

The control group was matched to the group of people with PD in terms of age. The PD group was split into several age groups with a 5-year range. The number of controls per age group was based on the percentage of people with PD in each age group. The highest possible number of controls in each age group was randomly selected from the total group of controls.

Handling missing or incorrect data

There were no missing data in the control group. PD data were removed case wise if missing answers exceeded 25% of SVCq items (n = 5). Missing answers that remained (0.2% of total data) were left missing for the frequency analysis of visual complaints. To be able to calculate total SVCq scores, missing values were imputed based on all available values using the Maximum Likelihood Estimation method. In ten PD cases, two answer boxes were checked on one of the 19 items. The answer representing the lowest frequency of visual complaints was preserved, in order to prevent an overestimation of visual complaints.

Determining the presence of ophthalmological conditions

We considered people with PD to be free of an OC if their medical file and their self-reported information were not suggestive of an OC. If they did report a clear condition or there was an OC mentioned in the medical file, they were considered having an OC. In the control group, the presence of an OC was based only on self-reported information. See S1 Table for an overview of OCs in both groups. We considered people who underwent cataract surgery (N = 38 in people with PD and N = 43 in the control group) to have an OC, given the possibility of residual long-term effects or secondary cataracts. Excluding these people did not alter the results.

Assumptions

All variables were either on interval (total score, number of complaints, impact on daily life (0–10 scale)) or ordinal level (scores on individual complaints) and measures were independent. The Kolmogorov-Smirnov tests showed that normality was violated for all variables. Therefore, non-parametric tests were used.

Prevalence of visual complaints

A frequency analysis was performed for people with PD and controls on each of the 19 complaints of the SVCq; percentages were calculated of persons answering ‘never/hardly’, ‘sometimes’, and ‘often/always’. Frequencies were compared between people with PD and controls using a Chi-Square test, complemented with adjusted residuals. Comparisons were made for each complaint. Taking multiple comparisons into account, Bonferroni’s correction resulted in an alpha of .008 (.05/6 = .008) and adjusted residuals of ≥ 2.64 to reach significance [19]. Effect sizes of Cramer’s V were calculated (small: .07 - .21, medium: .21 - .35, large: > .35) [20].

An additional frequency analysis was performed on the answers of people with PD to the first, open-ended question of the SVCq. These spontaneous complaints were categorized according to complaints listed in the structured part of the SVCq. If a complaint was different from SVCq complaints, a new category was created when the complaint was mentioned at least twice. When only mentioned once, complaints were added to the category ’Other’. Complaints were excluded if they were too unclear for interpretation (n = 9), evidently unrelated to vision (n = 3), referred to an OC (e.g., glaucoma; n = 17), or to having or needing glasses/contact lenses (n = 34). Two researchers were involved in the categorization process. In case of doubt, a third researcher was involved.

The number and impact of visual complaints and the relationship to other variables

SVCq total score, the impact on daily life score (0–10 scale), the total number of complaints (‘sometimes’ and ‘often/always’), and the number of complaints rated ‘often/always’ were calculated for all people with PD and controls. The total SVCq score was calculated by summing the numbers of each response to the 19 items (0 = ‘never/hardly’, 1 = ‘sometimes’, 2 = ‘often/always’). The relationship between these scores and age, disease duration and total Levodopa Equivalent Daily Dose (LEDD) of the PD group was calculated by Spearman’s correlations. In addition, Kruskal-Wallis and Mann-Whitney-U tests were performed to investigate differences in these scores between 1) people with PD and controls, 2) people with PD with and without an OC, and 3) people with PD and controls without an OC, 4) male and female people with PD, and 5) people with PD in different disease severity groups (H&Y 1, H&Y 2, H&Y 3, and ≥ H&Y 4). An alpha < .05 was considered to be significant. Coefficient r was calculated as an effect size (small: .1 - .3, medium: .3 - .5, large: .5–1.0) [21]. See our previous publication for results regarding the five subscales of the SVCq [13].

Results

In total, 614 patients filled out the SVCq, of which 33 did not meet the diagnosis of idiopathic PD. These people were excluded, leaving a PD group of 581 individuals. Selected from a group of 1402 controls, the matching procedure resulted in a control group of 583 individuals. Characteristics of both groups are presented in Table 1 (see also [13]).

Prevalence of visual complaints

Table 2 presents the prevalence of visual complaints in people with PD and controls. More than 90% of people with PD reported at least one complaint (‘sometimes’ or ‘often/always’; 90.7%, n = 527), and 61.3% (n = 356) reported five or more complaints. Of the controls, the majority also reported at least one complaint (85.9%, n = 501), and 39.3% reported five or more. The prevalence of the 19 visual complaints (‘often/always’) ranged from 2.1% to 21.7% in people with PD and from 0.3% to 11.0% in controls. Most frequently reported complaints in people with PD were unclear vision and trouble reading (> 20%), followed by trouble focusing, experiencing reduced contrast, being blinded by bright light, and needing more light (> 15%). Least common were complaints of shaky, jerky, shifting images, visual field, color vision, and painful eyes (< 5%). Nearly half of people with PD (42.3%, n = 246) indicated that they would appreciate advice or rehabilitation for their visual complaints.

Table 2. Overview of the frequencies of people with PD and controls experiencing the SVCq’s visual complaints, and results of Chi-square tests comparing the groups.

People with PD Controls
Complaint Prevalence (adjusted residuals) X 2 p Cramer’s V
Unclear vision 29.14 < .001* .16
Often/always 21.7% (5.4*) 10.1% (-5.4*)
Sometimes 39.8% (-2.1) 46.0% (2.1)
Never/hardly 38.6% (-1.9) 43.9% (1.9)
Trouble focusing 43.77 < .001* .19
Often/always 17.1% (6.4*) 5.3% (-6.4*)
Sometimes 34.7% (0.1) 34.3% (-0.1)
Never/hardly 48.3% (-4.1*) 60.4% (4.1*)
Double vision 73.83 < .001* .25
Often/always 10.8% (6.1*) 2.1% (-6.1*)
Sometimes 19.3% (5.4*) 8.4% (-5.4*)
Never/hardly 69.9% (-8.3*) 89.5% (8.3*)
Depth perception 29.61 < .001* .16
Often/always 10.2% (3.9*) 4.3% (-3.9*)
Sometimes 25.4% (3.2*) 17.7% (-3.2*)
Never/hardly 64.4% (-5.1*) 78.0% (5.1*)
Shaky, jerky, shifting images 18.73 < .001* .13
Often/always 2.1% (2.7*) 0.3% (-2.7*)
Sometimes 12.6% (3.3*) 6.9% (-3.3*)
Never/hardly 85.4% (-4.1*) 92.8% (4.1*)
Visual field 15.19 .001* .11
Often/always 3.4% (3.6*) 0.5% (-3.6*)
Sometimes 10.0% (1.4) 7.7% (-1.4)
Never/hardly 86.6% (-2.9*) 91.8% (2.9*)
Color vision 1.29 .525 .03
Often/always 2.2% (0.9) 1.5% (-0.9)
Sometimes 5.2% (0.7) 4.3% (-0.7)
Never/hardly 92.6% (-1.1) 94.2% (1.1)
Reduced contrast 27.76 < .001* .16
Often/always 16.1% (5.3*) 6.4% (-5.3*)
Sometimes 33.9% (-1.8) 38.9% (1.8)
Never/hardly 50.1% (-1.6) 54.7% (1.6)
Blinded by bright light 10.75 .005* .10
Often/always 16.8% (2.8*) 11.0% (-2.8*)
Sometimes 31.3% (-2.4) 37.9% (2.4)
Never/hardly 52.0% (0.3) 51.1% (-0.3)
Needing more light 57.24 < .001* .22
Often/always 16.6% (5.3*) 6.7% (-5.3*)
Sometimes 29.3% (4.2*) 18.7% (-4.2*)
Never/hardly 54.1% (-7.3*) 74.6% (7.3*)
Light/dark adjustment 7.48 .024 .08
Often/always 8.8% (2.4) 5.2% (-2.4)
Sometimes 25.7% (0.9) 23.5% (-0.9)
Never/hardly 65.6% (-2.1) 71.4% (2.1)
Seeing things that others do not 53.44 < .001* .21
Often/always 7.9% (5.0*) 1.7% (-5.0*)
Sometimes 24.8% (4.8*) 13.7% (-4.8*)
Never/hardly 67.2% (-6.9*) 84.6% (6.9*)
Distorted images 36.70 < .001* .18
Often/always 4.3% (4.0*) 0.7% (-4.0*)
Sometimes 10.4% (4.4*) 3.8% (-4.4*)
Never/hardly 85.3% (-5.9*) 95.5% (5.9*)
Painful eyes 7.81 .020 .08
Often/always 2.3% (1.6) 1.0% (-1.6)
Sometimes 15.9% (2.2) 11.5% (-2.2)
Never/hardly 81.9% (-2.7*) 87.5% (2.7*)
Dry eyes 17.17 < .001* .12
Often/always 11.9% (4.1*) 5.2% (-4.1*)
Sometimes 25.2% (-0.5) 26.4% (0.5)
Never/hardly 62.9% (-2.0) 68.4% (2.0)
Needing more time 68.56 < .001* .24
Often/always 11.7% (7.0*) 1.5% (-7.0*)
Sometimes 30.3% (3.3*) 21.8% (-3.3*)
Never/hardly 58.0% (-6.8*) 76.7% (6.8*)
Traffic 63.09 < .001* .23
Often/always 6.1% (6.7*) 1.0% (-6.7*)
Sometimes 13.0% (3.5*) 6.7% (-3.5*)
Never/hardly 81.0% (-6.9*) 92.3% (6.9*)
Looking for something 36.73 < .001* .18
Often/always 11.1% (4.6*) 1.5% (-4.6*)
Sometimes 20.5% (3.6*) 12.9% (-3.6*)
Never/hardly 68.5% (-5.7*) 85.6% (5.7*)
Reading 35.85 < .001* .18
Often/always 21.6% (5.2*) 10.3% (-5.2*)
Sometimes 29.3% (1.4) 25.7% (-1.4*)
Never/hardly 49.1% (-5.1*) 64.0% (5.1*)

Note: PD = Parkinson’s disease.

* = significant adjusted residual (> 2.64) or a significant p-value (α < .008).

All complaints were significantly more prevalent in people with PD compared to controls, except for complaints on light/dark adjustment, color vision and painful eyes. Based on adjusted residuals, differences between the two groups were found primarily in the response options ‘often/always’ and ‘never/hardly’. People with PD were more likely to rate their complaints ‘often/always’, while controls were more likely to rate their complaints ‘never/hardly’. Medium effect sizes were found for the complaints needing more light, needing more time, trouble with traffic participation, double vision, and seeing things that others do not. Other effect sizes were small. Fig 1 visually presents the prevalence of each visual complaint (‘often/always’) in both groups.

Fig 1. Prevalence of visual complaints reported ‘often/always’ by people with Parkinson’s disease and age-matched controls.

Fig 1

* = significant difference between the groups (α < .008).

Analysis of responses to the open-ended question of the SVCq revealed that 52% (n = 299) of people with PD reported at least one spontaneous visual complaint (544 complaints in total). Most complaints were similar to structured SVCq items (79%; see Table 3). These complaints were also the most prevalent; i.e., unclear vision (19.3%, n = 112) and difficulty reading (15.0%, n = 87) were most frequently reported, followed by double vision (11.2%, n = 65) and needing more light (6.0%, n = 35). Complaints dissimilar to SVCq items were also reported, though much less frequently; i.e., most frequently reported complaints were difficulty watching a display/TV (3.8%, n = 22) and tiredness while doing visual tasks (3.8%, n = 22).

Table 3. Visual complaints reported spontaneously on the first, open-ended question of the SVCq by people with PD.

Spontaneous complaints similar to structured SVCq items, % (n) Spontaneous complaints not similar to structured SVCq items, % (n)
Unclear vision 23.2% (135) Difficulty watching a display/TV 3.8% (22)
Reading 15.0% (87) Tiredness during visual tasks 3.8% (22)
Double vision 11.2% (65) Difficulty with distant vision 3.3% (19)
Needing more light 6.0% (35) Vision varies during the day 2.6% (15)
Trouble focusing 3.4% (20) Tearing of the eyes 1.7% (10)
Traffic 3.1% (18) Eyelids close unwillingly <1% (5)
Seeing things that others do not 2.9% (17) Difficulty seeing details/small things <1% (3)
Painful eyes 1.9% (11) Difficulty with near vision <1% (2)
Depth perception 1.7% (10) Itchy eyes <1% (2)
Visual field 1.4% (8) Squeezing/squinting the eyes <1% (2)
Blinded by bright light 1.2% (7) Other 2.1% (12)
Reduced contrast 1.0% (6)
Shaky, jerky, shifting images <1% (4)
Distorted images <1% (2)
Dry eyes <1% (2)
Looking for something <1% (2)
Needing more time <1% (1)
Total 79% (430) 21% (114)

Note: PD = Parkinson’s disease; SVCq = Screening Visual Complaints questionnaire.

The number and impact of visual complaints and the relationship to other variables

People with PD reported significantly more complaints on the SVCq than controls (see Table 4). They had a higher total score, and a higher number of complaints (‘sometimes’ & ‘often/always’, and ‘often/always). In addition, they reported a greater impact of visual complaints on their daily lives. Effect sizes were all small.

Table 4. SVCq scores of people with PD and the control group, with Mann-Whitney U test results.

People with PD (n = 581) Controls (n = 583)
M ± SD Median M ± SD Median U p r
Total SVCq score 8.42 ± 7.27 7.00 5.19 ± 5.13 4.00 124430.5 < .001* 0.23
Impact on daily life score 3.16 ± 2.68 3.00 2.65 ± 2.52 2.00 148938.5 .002* 0.09
N complaints ‘sometimes’ & ‘often/always’ 6.37 ± 4.67 6.00 4.43 ± 3.80 4.00 128025.5 < .001* 0.21
N complaints ‘often/always’ 2.02 ± 3.04 1.00 0.76 ± 1.79 0.00 126403.5 < .001* 0.25

Note: M = mean; n = number; PD = Parkinson’s disease; SD = standard deviation.

* = significant p-value (α < .05).

Table 5 shows that people with PD with an OC reported significantly more complaints than those without an OC on all SVCq measures. In addition, a significant difference was found for most SVCq measures between people with PD without an OC and controls without an OC. No significant differences were found between these groups with regard to the impact on daily life experienced due to the presence of visual complaints (0–10 scale). Effect sizes for all comparisons were small.

Table 5. SVCq scores of people with and without an ophthalmological condition, with Mann-Whitney U test results.

PD OC+ (n = 203) PD OC- (n = 351) Control OC- (n = 407) PD OC+ vs. PD OC- PD OC- vs. Control OC-
M ± SD Median M ± SD Median M ± SD Median U p r U p r
Total SVCq score 10.33 ± 8.16 8.00 7.32 ± 6.59 6.00 4.61 ± 4.32 4.00 27760.0 < .001* 0.20 55159.0 < .001* 0.24
Impact on daily life score 3.77 ± 2.94 3.00 2.78 ± 2.47 2.00 2.52 ± 2.48 2.00 27832.0 < .001* 0.18 66161.0 .148 0.05
N complaints ‘sometimes’ & ‘often/always’ 8.50 ± 4.10 8.00 5.74 ± 4.48 5.00 4.04 ± 3.52
3.00 22637.5 < .001* 0.29 56189.0 < .001* 0.20
N complaints ‘often/always’ 2.73 ± 3.11 2.00 1.58 ± 2.58 0.00 0.57 ± 1.14 0.00 25636.5 < .001* 0.20 56132.0 < .001* 0.25

Note: M = mean; n = number; OC+ = people with an ophthalmological condition; OC- = people without an ophthalmological condition; PD = Parkinson’s disease; SD = standard deviation.

* = significant p-value (α < .05).

The Kruskal-Wallis test performed on people with PD in different H&Y stages showed that all SVCq measures differed significantly between the groups (see Table 6A). The Mann-Whitney U comparing individual groups (see Table 6B) resulted in multiple differences, all indicating that people with PD in higher H&Y stages experienced more prevalent and more severe complaints. There were no differences between H&Y stage 1 and 2. Comparisons between other groups (1 vs. 3, 2 vs. 3, and 3 vs. ≥ 4) all revealed some significant differences. The comparisons 1 vs. ≥ 4 and 2 vs. ≥ 4 revealed significant differences for all SVCq measures. The total SVCq score, and the number of complaints (‘sometimes’ & ‘often/always’) showed significant differences in all comparisons (except 1 vs. 2). Most effect sizes were small. Medium effect sizes were found for comparisons of the groups 1, 2, and 3 with group ≥ 4 regarding the SVCq total score and the number of complaints (‘often/always’). Most medium effect sizes were found for the comparison between group 1 and ≥ 4.

Table 6. a. SVCq scores of people with PD in different disease severity stages, with Kruskal-Wallis test results.

b. SVCq scores of people with PD in different disease severity stages, with Mann-Whitney U test results.

H&Y 1 (n = 125) H&Y 2 (n = 218) H&Y 3 (n = 101) H&Y ≥ 4 (n = 49)
M ± SD Median M ± SD Median M ± SD Median M ± SD Median H df p
Total SVCq score 7.66 ± 7.38 6.00 7.56 ± 6.61 6.00 8.94 ± 6.59 7.00 13.54 ± 7.83 14.00 29.40 3 < .001*
Impact on daily life score 2.78 ± 2.57 2.00 3.05 ± 2.64 2.00 3.33 ± 2.56 3.00 4.69 ± 2.53 5.00 19.29 3 < .001*
N complaints ‘sometimes’ & ‘often/always’ 5.86 ± 4.79 5.00 5.86 ± 4.23 5.00 6.94 ± 4.48 6.00 9.39 ± 4.80 9.00 24.97 3 < .001*
N complaints ‘often/always’ 1.78 ± 3.01 0.00 1.69 ± 2.86 0.00 1.96 ± 2.51 1.00 4.08 ± 3.56 4.00 30.78 3 < .001*

Note: H&Y = Hoehn and Yahr staging [15]; M = mean; n = number; PD = Parkinson’s disease; SD = standard deviation.

* = significant p-value (α < .05).

Most measures did not indicate a difference between the sexes (see Table 7). Females did experience complaints significantly more frequently ‘often/always’. However, effect sizes were small. Age, disease duration, and LEDD showed significant positive correlations with all SVCq measures (see Table 8). Correlations were all weak [22].

Table 7. SVCq scores of male and female individuals with PD, with Mann-Whitney U test results.

Males with PD (n = 354) Females with PD (n = 227)
M ± SD Median M ± SD Median U p r
Total SVCq score 8.09 ± 7.30 6.00 8.95 ± 7.21 7.00 36612.5 0.070 0.08
Impact on daily life score 3.14 ± 2.64 3.00 3.20 ± 2.75 2.00 38417.5 0.886 0.01
N complaints ‘sometimes’ & ‘often/always’ 6.14 ± 4.69 5.00 6.73 ± 4.62 6.00 36957.5 0.102 0.07
N complaints ‘often/always’ 1.93 ± 3.06 0.00 2.17 ± 3.01 1.00 36345.5 0.039* 0.09

Note: M = mean; n = number; PD = Parkinson’s disease; SD = standard deviation.

* = significant p-value (α < .05).

Table 8. Spearman’s correlations between SVCq scores and age, disease duration, and LEDD of people with PD.

Age Disease duration LEDD
Total SVCq score r = .118, p = .004* r = .213, p = < .001* r = .242, p = < .001*
Impact on daily life score r = .103, p = .014* r = .236, p = < .001* r = .235, p = < .001*
N complaints ‘sometimes’ & ‘often/always’ r = .102, p = .014* r = .195, p = < .001* r = .233, p = < .001*
N complaints ‘often/always’ r = .141, p = .001* r = .220, p = < .001* r = .224, p = < .001*

Note: LEDD = Levodopa equivalent daily dose; n = number; PD = Parkinson’s disease.

* = significant p-value (α < .05).

Discussion

In this study, we investigated the prevalence of a wide variety of function and activity related visual complaints in a large group of people with PD, compared with an age-matched control group. Additionally, the relationship with several demographic and disease-related factors was examined.

Visual complaints were more prevalent in people with PD compared to controls, consistent with previous findings [2]. All 19 complaints were more prevalent in people with PD compared to controls, and 16 complaints showed significant differences. In most cases, the frequency of controls experiencing complaints ‘sometimes’ was comparable to people with PD. However, people with PD experienced complaints more frequently ‘often/always’. This finding is important considering that the frequency in which a complaint is reported is closely related to its impact in daily life [23]. Furthermore, in contrast to controls, people with PD often reported more complaints concurrently. This might explain that people with PD experienced a greater impact of visual complaints on their daily lives (scale 0–10) compared to controls.

Most common in people with PD were complaints regarding unclear vision, reading, and trouble focusing. This is in line with previous literature indicating that blurred vision and reading difficulties were one of the most common visual complaints in people with PD [2]. Complaints of altered color vision and visual field deficits were less prevalent in previous studies [2]. Our study confirms these results, where these complaints, along with painful eyes and shaky, jerky, shifting, and distorted images, were least common. The largest differences between people with PD and controls were related to the complaints needing more light, needing more time, traffic participation, double vision, and seeing things that others do not. It can be concluded that these complaints are more unique to people with PD. The fact that these complaints stand out might be the reason that there is already more attention for some of these complaints than there is for others. For example, there are numerous studies on hallucinations [24], and double vision and oversensitivity to light are incorporated in widely used questionnaires [2527]. However, even though other complaints stand out less, these are still highly prevalent and might be as bothersome in daily life [2].

The presence of an identified (diagnosed or self-reported) OCs related to the prevalence of visual complaints, evident from the differences found between people with PD with and without identified OCs. However, we showed that even without identified OCs, people with PD experienced more visual complaints than controls. We do have to mention that the presence of OCs may have been underestimated. Medical records and self-reported information of people with PD may not fully reflect the OCs present, for example because OCs may be underdiagnosed in people with PD [4]. In controls, we only had access to self-reported information. Therefore, there is a risk of underestimation in both groups. Conclusions regarding the analyses with OCs should therefore be drawn with caution.

Besides OCs, there might be other factors relating to the presence of visual complaints, which might be subject of future studies. There may for example be detectable visual function deficits associated with complaints. Common complaints in our study were unclear vision, trouble focusing, and difficulty reading. These may be associated with oculomotor deficits. Previous research shows that oculomotor deficits occur regularly in people with PD and influence clarity of vision, the ability to focus, and reading [28]. In addition, people with PD with oculomotor deficits are reported to experience double vision and difficulty driving [28], complaints that were, relative to controls, also very common in PD in our study. Moreover, complaints that may be less dependent on precise eye movements, such as visual field loss and altered color vision, we found to be least common.

However, as was previously shown by others in visual and cognitive domains (Van der Feen et al., submitted) [29], functional deficits might also not strongly relate to the presence of complaints. There may not be a clear one-to-one relationship between complaints and objective functional deficits. In addition, the pathophysiology of PD, including disturbances in retinal, cortical or thalamic functioning, may relate to visual complaints as well [1]. This is supported by our finding that longer disease duration and increasing severity of PD resulted in more visual complaints. Furthermore, as was also shown by previous studies, we found that the amount of antiparkinsonian medication related to the presence of visual complaints as well [3032].

Clinical implications

It is highly important to screen for a large range of visual complaints, since each complaint might have its own negative impact on the daily lives of people with PD. Furthermore, each complaint might require another type of treatment. By addressing complaints that are most bothersome for that particular person, the negative impact on the daily lives of people with PD can be reduced to a minimum.

When a person indicates having visual complaints, possible underlying OCs and visual functions may be assessed to identify and, if possible, treat them. Some underlying disorders might be well treated (e.g., dry eyes or cataract) and relieve complaints. However, not all OCs can be treated (e.g., in the presence of oculomotor deficits). Moreover, it may be that complaints not always directly relate to an underlying OC or functional disorder, and relate to the presence of PD itself, or factors related to it (e.g., medication). When this is the case, advice, aids or rehabilitation is required to reduce complaints (e.g., use of a fixed reading distance in case of oculomotor deficits).

Regardless of the cause, timely recognition of visual complaints is important. As PD is a progressive and fluctuating disease, frequent mapping of visual complaints is advised. This is supported by our finding that age, disease duration and severity relate to the occurrence of visual complaints. Since a person might not report visual complaints themselves, standardized questioning is advised. Especially considering that a large proportion of people with PD (42.3%) indicated that they would appreciate advice or rehabilitation for their visual complaints.

When using the SVCq in clinical practice, one could use total or subscale scores to get a clear and general impression of the visual complaints a person experiences, a method supported by our previous study [13]. Additionally, this study illustrates that it may be important to look at individual items of the questionnaire as well. Complaints are not equally common (e.g., we see that dry eyes are more common than painful eyes from the same subscale) and may be distributed differently among individuals. By taking individual complaints into account, care can be tailored specifically to each individual.

Strengths, limitations and recommendations for future research

This is one of few studies aiming at improving the knowledge on visual complaints in people with PD. Most previous studies on visual complaints included relatively small groups or used measures that captured only one or a few complaints [2]. By including a large cohort of people with PD, and an age-matched control group, we were able to draw conclusions more representative for the whole population. In addition, we were able to examine a wide variety of visual complaints by using the SVCq.

Other screening questionnaires, like the 25-list-item version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and the more recently developed Visual Impairment in Parkinson’s Disease Questionnaire (VIPD-Q) primarily aim to detect vision-related quality of life or symptoms of OCs, respectively [23,33]. In contrast, the SVCq is aimed at assessing a broader range of visual complaints at a functional and activity level and can be used as a guide for treatment or rehabilitation, by focusing on a person’s priorities, regardless of the presence of OCs. We do recognize the possibility that OCs or visual function deficits may relate to complaints, as was also suggested by results of our study. However, this study also showed the possibility of complaints occurring in the absence of an identified OC. This underlines the added value of screening for self-reported complaints as well.

Another difference with previous questionnaires is that the SVCq starts with an open-ended question. This allows people to report complaints that are most important to them, without being influenced by the content or direction of the question itself. This seems a valuable addition for rehabilitation purposes. Firstly, it gives an indication of which complaints may be most prominent or relevant to a person, which guides intervention goals. Secondly, it may provide additional information on complaints that are not (fully) covered by structured items of the questionnaire (e.g., a person may have a complaint especially when they are tired, or during a specific time of the day). Although the open-ended question is a valuable addition, it should not be seen as a substitute for the structured items, as our study showed that people with PD may not report complaints spontaneously, whereas they do when specifically asked. Moreover, based on complaints reported on the open-ended question, it appears that the most prevalent spontaneously reported complaints of people with PD are covered by the structured SVCq items, providing additional supporting evidence for the validity of the questionnaire.

A possible limitation of this study is that data of people with PD were collected in an outpatient clinic, which is not visited by people that are bedridden. Therefore, people with PD in the highest disease stages were underrepresented in this study. Because the prevalence of visual complaints is related to disease stage, our prevalence of complaints may have been underestimated. Nonetheless, this study provides clear insight into the complaints of an outpatient population.

The method of data collection differed for the two groups. Whereas people with PD had the choice of how to complete the questionnaire (online or on paper), controls completed the questionnaire online. In the online setting, people could not continue with the questionnaire until they had given an answer. We were unable to control for this when people completed the questionnaire on paper, which resulted in some missing or unclear data in the group of people with PD. However, missing data was few and randomly distributed. We do not expect that different collection methods led to different response patterns [34].

It cannot be ruled out that comorbidities (e.g., neurological or psychiatric conditions) could have explained part of the complaints experienced by people with PD. For example, stroke is likely to influence vision [35]. Comorbidities were allowed in the PD group, while severe disorders (like a stroke) were excluded in the control group. By allowing comorbidities, however, we did create a representative group of people with PD. Furthermore, we included a large sample, which leads to an accurate estimation of visual complaints in the population. Future studies could consider investigating the influence of other comorbidities on visual complaints in PD.

We had no access to information such as ethnicity and socioeconomic status, or symptoms of anxiety and depression, or cognitive impairment in either group. Since these variables might influence the presence and the extent to which people report visual complaints, this could be subject to future research [3638].

Conclusion

People with PD experience a wide range of visual complaints, which occur more frequently in people with PD compared to controls. These complaints seem to evolve with progressing disease characteristics and medication use. Since visual complaints can have a vast impact on the daily lives of people with PD, standardized questioning is advised for timely recognition and treatment.

Supporting information

S1 Table. Ophthalmological conditions in people with PD and age-matched control.

(PDF)

S2 Table. Screening visual complaints questionnaire–Dutch version.

(PDF)

S3 Table. Screening visual complaints questionnaire–English version.

(PDF)

Acknowledgments

Research support: E.A. van de Klundert (BSc), Psychology student at the University of Groningen.

Disclosure

Data from the samples included in this study have been used in a previous study to answer different research questions (I. van der Lijn, G.A. de Haan, F.E. van der Feen, F. Huizinga, A.B.M. Fuermaier, T. van Laar, J. Heutink, The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson’s disease—Confirmatory factor analysis and advice for its use in clinical practice, PLoS One. 17 (2022) 1–14. https://doi.org/10.1371/journal.pone.0272559) [13].

Data Availability

The data that support the findings of this study are available from DataverseNL. Because of ethical reasons, restrictions apply to the availability of these data (i.e., the combination of variables can potentially lead to participants being identified). Data are available at https://doi.org/10.34894/ODVGUV with the permission of the ethics board of the Faculty of Behavioral and Social Sciences, University of Groningen (contact: dcc@rug.nl).

Funding Statement

This work was supported by Visio Foundation, Amsterdam, The Netherlands (JH, GdH, FvdF, IvdL, CS; https://visiofoundation.org/), and ZonMw grant 637005001 (JH, GdH, FvdF, IvdL, CS; Expertisefunctie Zintuiglijk Gehandicapten, Meerjarig deelsectorplan 2020-2022 Visueel; https://www.zonmw.nl/nl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Weil R.S., Schrag A.E., Warren J.D., Crutch S.J., Lees A.J., Morris H.R., Visual dysfunction in Parkinson’s disease, Brain. (2016). doi: 10.1093/brain/aww175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.van der Lijn I., de Haan G.A., Huizinga F., van der Feen F.E., Rutgers A.W.F., Stellingwerf C., et al. , Self-Reported Visual Complaints in People with Parkinson’s Disease: A Systematic Review, J. Parkinsons. Dis. (2022) 1–22. 10.3233/jpd-202324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Savitt J., Mathews M., Treatment of Visual Disorders in Parkinson Disease, Curr. Treat. Options Neurol. 20 (2018). doi: 10.1007/s11940-018-0519-0 [DOI] [PubMed] [Google Scholar]
  • 4.Ekker M.S., Janssen S., Seppi K., Poewe W., de Vries N.M., Theelen T., et al., Ocular and visual disorders in Parkinson’s disease: Common but frequently overlooked, Park. Relat. Disord. (2017). doi: 10.1016/j.parkreldis.2017.02.014 [DOI] [PubMed] [Google Scholar]
  • 5.Hamedani AG W.A., Self-reported visual dysfunction in Parkinson disease: the Survey of Health, Ageing and Retirement in Europe, Eur J Neurol. 27 (2020) 484–489. doi: 10.1111/ene.14092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Reddy P., Martinez-Martin P., Brown R.G., Chaudhuri K.R., Lin J.P., Selway R., et al., Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: Preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD), Health Qual. Life Outcomes. (2014). 10.1186/1477-7525-12-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hobart J.C., Freeman J.A., Lamping D.L., Physician and patient-oriented outcomes in progressive neurological disease: Which to measure?, Curr. Opin. Neurol. (1996). doi: 10.1097/00019052-199612000-00008 [DOI] [PubMed] [Google Scholar]
  • 8.Chaudhuri K.R., Prieto-Jurcynska C., Naidu Y., Mitra T., Frades-Payo B., Tluk S., et al., The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: An international study using the nonmotor symptoms questionnaire, Mov. Disord. 25 (2010) 704–709. doi: 10.1002/mds.22868 [DOI] [PubMed] [Google Scholar]
  • 9.de Vries S.M., Heutink J., Melis-Dankers B.J.M., Vrijling A.C.L., Cornelissen F.W., Tucha O., Screening of visual perceptual disorders following acquired brain injury: A Delphi study, Appl. Neuropsychol. 25 (2018) 197–209. doi: 10.1080/23279095.2016.1275636 [DOI] [PubMed] [Google Scholar]
  • 10.Postuma R.B., Gagnon J.F., Montplaisir J., Clinical prediction of Parkinson’s disease: Planning for the age of neuroprotection, J. Neurol. Neurosurg. Psychiatry. 81 (2010) 1008–1013. doi: 10.1136/jnnp.2009.174748 [DOI] [PubMed] [Google Scholar]
  • 11.Werheid K., Koch I., Reichert K., Brass M. , Impaired self-initiated task preparation during task switching in Parkinson’s disease, Neuropsychologia. 45 (2007) 273–281. doi: 10.1016/j.neuropsychologia.2006.07.007 [DOI] [PubMed] [Google Scholar]
  • 12.Huizinga F., Heutink J., de Haan G.A., van der Lijn I., van der Feen F.E., Vrijling A.C.L., et al., The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric features in a community sample, PLoS One. 15 (2020). 10.1371/journal.pone.0232232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.van der Lijn I., de Haan G.A., van der Feen F.E., Huizinga F., Fuermaier A.B.M., van Laar T., et al., The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson’s disease—Confirmatory factor analysis and advice for its use in clinical practice, PLoS One. 17 (2022) 1–14. 10.1371/journal.pone.0272559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gibb WRG, Lees AJ, Occasional review: the relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease, J Neurol Neurosurg Psychiatry. 51 (1998) 745–752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hoehn M.M., Yahr M.D., Parkinsonism: onset, progression, and mortality. 1967., Neurology. 50 (1998). doi: 10.1212/wnl.50.2.318 [DOI] [PubMed] [Google Scholar]
  • 16.de Vent N.R., Agelink van Rentergem J.A., Kerkmeer M.C., Huizenga H.M., Schmand B.A., Murre J.M.J., Universal Scale of Intelligence Estimates (USIE): Representing Intelligence Estimated From Level of Education, Assessment. 25 (2018) 557–563. doi: 10.1177/1073191116659133 [DOI] [PubMed] [Google Scholar]
  • 17.Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E., Systematic review of levodopa dose equivalency reporting in Parkinson’s disease, Mov. Disord. 25 (2010) 2649–2653. doi: 10.1002/mds.23429 [DOI] [PubMed] [Google Scholar]
  • 18.IBM Corp., IBM SPSS Statistics for Windows, Version 26.0, (2019) Armonk, NY: IBM Corp. [Google Scholar]
  • 19.MacDonald P.L., Gardner R.C., Type I error rate comparisons of post hoc procedures for I × J chi-square tables, Educ. Psychol. Meas. 60 (2000) 735–754. 10.1177/00131640021970871. [DOI] [Google Scholar]
  • 20.Kim H.-Y., Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test, Restor. Dent. Endod. 42 (2017) 152. 10.5395/rde.2017.42.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cohen J., Statistical Power Analysis for the Behavioral Sciences, New York, 1998. [Google Scholar]
  • 22.Akoglu H., User’s guide to correlation coefficients, Turkish J. Emerg. Med. 18 (2018) 91–93. doi: 10.1016/j.tjem.2018.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Borm C.D.J.M., Visser F., Werkmann M., De Graaf D., Putz D., Seppi K., et al., Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire, Neurology. 94 (2020) E1539–E1547. doi: 10.1212/WNL.0000000000009214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Diederich N.J., Fénelon G., Stebbins G., Goetz C.G., Hallucinations in Parkinson disease, Nat. Rev. Neurol. (2009). doi: 10.1038/nrneurol.2009.62 [DOI] [PubMed] [Google Scholar]
  • 25.Chaudhuri K.R., Martinez-Martin P., Brown R.G., Sethi K., Stocchi F., Odin P., et al., The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study, Mov. Disord. 22 (2007) 1901–1911. doi: 10.1002/mds.21596 [DOI] [PubMed] [Google Scholar]
  • 26.Chaudhuri K.R., Martinez-Martin P., Schapira A.H.V., Stocchi F., Sethi K., Odin P., et al., International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study, Mov. Disord. 21 (2006) 916–923. doi: 10.1002/mds.20844 [DOI] [PubMed] [Google Scholar]
  • 27.Visser M., Marinus J., Stiggelbout A.M., van Hilten J.J., Assessment of autonomic dysfunction in Parkinson’s disease: The SCOPA-AUT, Mov. Disord. 19 (2004) 1306–1312. doi: 10.1002/mds.20153 [DOI] [PubMed] [Google Scholar]
  • 28.Berliner J.M., Kluger B.M., Corcos D.M., Pelak V.S., Gisbert R., McRae C., et al., Patient perceptions of visual, vestibular, and oculomotor deficits in people with Parkinson’s disease, Physiother. Theory Pract. 36 (2020) 701–708. doi: 10.1080/09593985.2018.1492055 [DOI] [PubMed] [Google Scholar]
  • 29.Vlagsma T.T., Koerts J., Tucha O., Dijkstra H.T., Duits A.A., van Laar T., et al., Objective Versus Subjective Measures of Executive Functions: Predictors of Participation and Quality of Life in Parkinson Disease?, Arch. Phys. Med. Rehabil. 98 (2017) 2181–2187. doi: 10.1016/j.apmr.2017.03.016 [DOI] [PubMed] [Google Scholar]
  • 30.Brandt A.U., Zimmermann H.G., Oberwahrenbrock T., Isensee J., Müller T., Paul F., Self-perception and determinants of color vision in Parkinson’s disease, J. Neural Transm. 125 (2018) 145–152. doi: 10.1007/s00702-017-1812-x [DOI] [PubMed] [Google Scholar]
  • 31.Schindlbeck K.A., Schönfeld S., Naumann W., Friedrich D.J., Maier A., Rewitzer C., et al., Characterization of diplopia in non-demented patients with Parkinson’s disease, Park. Relat. Disord. 45 (2017) 1–6. doi: 10.1016/j.parkreldis.2017.09.024 [DOI] [PubMed] [Google Scholar]
  • 32.McDowell S.A., Harris J.P., Visual problems in Parkinson’s disease: A questionnaire survey, Behav. Neurol. 10 (1997) 77–81. doi: 10.3233/BEN-1997-102-305 [DOI] [PubMed] [Google Scholar]
  • 33.Mangione C.M., Lee P.P., Gutierrez P.R., Spritzer K., Coleman A.L., Development of the 25-item National Eye Institute visual function questionnaire, Evidence-Based Eye Care. 3 (2002) 58–59. 10.1097/00132578-200201000-00028. [DOI] [PubMed] [Google Scholar]
  • 34.Čandrlić S., Katić M.A., Dlab M.H., Online vs. Paper-based testing: A comparison of test results, 2014 37th Int. Conv. Inf. Commun. Technol. Electron. Microelectron. MIPRO 2014—Proc. (2014) 657–662. 10.1109/MIPRO.2014.6859649. [DOI] [Google Scholar]
  • 35.Pula J.H., Yuen C.A., Eyes and stroke: The visual aspects of cerebrovascular disease, Stroke Vasc. Neurol. 2 (2017) 210–220. doi: 10.1136/svn-2017-000079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Chua C.Y., Koh M.R.E., Chia N.S.Y., Ng S.Y.E., Saffari S.E., Wen M.C., et al. , Subjective cognitive Complaints in early Parkinson’s disease patients with normal cognition are associated with affective symptoms, Park. Relat. Disord. 82 (2021) 24–28. doi: 10.1016/j.parkreldis.2020.11.013 [DOI] [PubMed] [Google Scholar]
  • 37.Tielsch J.M., Sommer A., Katz J., Quigley H., Ezrine S., Socioeconomic Status and Visual Impairment Among Urban Americans, Arch. Ophthalmol. 109 (1991) 637–641. 10.1001/archopht.1991.01080050051027. [DOI] [PubMed] [Google Scholar]
  • 38.Congdon N., Causes and Prevalence of Visual Impairment among Adults in the United States, Arch. Ophthalmol. 122 (2004) 477–485. doi: 10.1001/archopht.122.4.477 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Thiago P Fernandes

11 Oct 2022

PONE-D-22-24932Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Use of the Screening Visual Complaints questionnairePLOS ONE

Dear Dr. van der Lijn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Thiago Fernandes, Sp. Neuro, EbS, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. 

" Parts of the same data were used for publication of our research article "The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson’s disease - Confirmatory factor analysis and advice for its use in clinical practice". This does not constitute dual publication, since the earlier publication focused on the validation and use of the questionnaire in a clinical population. In contrast, the current submission uses the questionnaire scores of people with Parkinson's disease with the aim of providing insight into the prevalence of their visual complaints and contributing risk factors."

Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Additional Editor Comments:

Reviewers have now commented on your study. You will see that we require some amendments to be made before we are able to proceed. 

If you are prepared to undertake the work required, I would be pleased to forward for publication. For your guidance, reviewers' comments are appended below. 

Most of the comments were very quick-to-solve and, overall, we find your study very interesting. You also will notice that some of the comments are really specific, so please be cautious when arguing & making the necessary amendments. 

Please respond to the Reviewer's comments in a separate letter AND highlight all changes in the manuscript. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Partly

Reviewer #5: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The fact that visual complaints cannot be fully explained by ophthalmological conditions is not a surprise. Several diseases affecting the central nervous system cause visual disturbances that cannot be detected during the standard ocular and visual examinations. Therefore, research addressing visually guided behaviors and self-reported visual performance is quite relevant in patients with progressive diseases affecting the brain,

It was interesting to learn from the Authors that PD patients are at high risk of visual complaints such as trouble to reading and focusing. These alterations are likely associated, at least partially, with oculomotor impairments since other visual attributes that may be less dependent on precise fixational eye movements, such as visual field and color vision, showed much lower prevalence.

I would like to congratulate the Authors for their great work and well-organized report. I recommend to include in the discussion a brief description concerning the above-mentioned possible associations between visual disturbances and oculomotor alterations in PD patients that may be a subject of future investigations.

Reviewer #2: The study entitled "Prevalence and nature of self-reported visual complaints in people with Parkinson’s

disease - Use of the Screening Visual Complaints questionnaire" is well executed. The authors have made a clear investigation and have prepared the questionnaires to include most common visual defects for early diagnosis among PD patients. However, the authors need to clarify few aspects,

1. In the introduction the authors can write more about the visual defects that are reported among PD patients with relevance to their stage of PD

2. Whether any subsequent ophthalmic examinations were carried out on the self-reported patients to confirm the nature of the visual condition, like assessing their visual acuity to further confirm ? unclear vision appears to be a pre-dominant complaint with 23.2% reporting, so having a simple visual acuity test on these patients would have added more value to the data.

3. Did the authors consider analyzing the data from PD cases based on their stage of the disease apart from classifying based on their age, if so how was the correlation between the visual condition and stages ? This would provide some insight on the ophthalmic deterioration with relevance to the severity of the PD.

4. How the co-morbidity of diabetes among the PD cases were considered ? and does the control group contains diabetes cases ?

5. The authors need to clarify how many of the PD cases reported here were under dopaminergic medication and also of the total PD cases reported how many were freshly identified to have PD and without taking any dopaminergic medication ?

6. Also it would be nice to record the sleep patterns of the PD patients especially those undergoing dopaminergic treatment and correlate with the visual condition ?

Reviewer #3: The manuscript reports an investigation of visual complaints in a population of Parkinson Disease's patients and compared to age-matched controls. I have some minor points to improve the manuscript's quality.

Abstract

Please indicate the numerical prevalence in the results.

Introduction

The Introduction is short, I suggest a paragraph fastly citing the more important or known visual complaints. It would be informative for a general audience.

Methods

Was there some information about the socioeconomic profile from PD patients and controls? If not, include as limitation.

Results

Figure 1 has no legend in the Y- and X- axis, and the numbers have low contrast. I suggest to include the legends and paint in black the numbers and letters. Why is not indicated the statistical difference?

Discussion

-The methods of data collection in PD patients and controls were different and it is an limitation of the study. The authors should discuss about it.

Reviewer #4: 1. The title can be “Prevalence and …….. - Screening Visual Complaints questionnaire outcome” or "outcome of SV...Q"; instead of “Use of the Screening Visual Complaints questionnaire”.

2. Line 69, please define mild, severe, and moderate condition staging.

3. Your control group had mild PD (line 67)? How is that not affecting your comparison with those having PD?

4. “Dutch-speaking people were invited” implies they can be of any ethnicity speaking dutch. Is ethnicity a factor affecting PD? (DOI: 10.3233/JPD-191763)

5. Are your study participants “people” or are they “patients” of the center?

6. Line 154, mentioning Evdk as a research assistant is unnecessary. “Two researchers” is enough.

7. The authors themselves published a systematic review of “Self-reported visual complaints in PD” in 2022 (DOI: 10.3233/JPD-202324). Moreover, the svc questionnaire you have used is an existing one (with a similar sample size and control group DOI: 10.1371/journal.pone.0272559), used previously and the results are in the systematic review itself. Please explain in detail the need for this study and what additional this study is achieving, that others could not before using the same questionnaire. Basically, how did you overcome the limitations of previous studies (if any).

8. Line 84-85, “In addition, a clear and clinically relevant factor structure has been demonstrated in people with PD” is unclear, please restructure.

9. Although PD patients were previously diagnosed and taken from medical files, please explain the diagnostic criteria of PD and staging and also for the control group.

10. Please explain in detail the ophthalmological examination conducted on the PD and control group.

11. Including people both with and without cataract surgery in the PD and control group, are you introducing any kind of bias or not? (Although you have mentioned excluding them did not alter the results). Please discuss this.

12. Conclusion: “Since visual complaints can have a vast impact on the daily lives of people with PD” Have you tested the QOL in people with PD in this study? Either add a reference or remove the line.

13. Tables 7 and 8 look unnecessary. Adding results is enough.

Reviewer #5: Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease- Use of the Screening of Visual Complaints questionnaire

This paper describes the prevalence of visual complaints in people with PD compared to a healthy control group. This subject is relevant and interesting. It deserves more attention in both research and clinical practice, and I agree with standardized screening for ophthalmological problems and disorders However, I do have a few questions and suggestions that may improve the contribution.

- First, I think both the introduction and discussion need some work. It is clear that this is an underrecognized topic and in need of more study. However, I think that these sections lack a good representation of the work that has already been performed on this subject. The introduction should, in addition, also indicate what this study adds to the current literature.

What is truly new (in my opinion tables 5-8) and how could this help to improve health care? Do we need screening by the ophthalmologist based on this study? And on which ophthalmological diseases? It is difficult to treat only complaints without knowing what the underlying disorders might be. It is stated in the discussion that some complaints (most seen in PD) are possible PD pathology related. This is interesting however there is no explanation on this topic.

- In the discussion section, also a more in-depth discussion of the causes and consequences of the findings and a comparison with previous studies should be made. Now only the rationale that screening is important because of a high prevalence and a potential impact on daily life, is repeated several times in both the introduction and discussion.

- The SVCq is introduced as a questionnaire that screens for visual complaints in people with neurodegenerative diseases. However, the questionnaire was validated in people without neurological conditions. Please explain.

- How was the question on dry eyes established? Dry eyes syndrome is a diagnosis and not typically a visual complain. Dry eyes could lead to symptoms of paradoxically to watery/teary eyes, burning/sandy/itchy eyes and/or blurred vision.

- The conclusion drawn in the discussion that the SVCq is very different from other questionnaires such as the VFQ-25 and the VIPD-questionnaire is not clear to me. When compared especially the VIPD-Q and the SVCq many questions are similar, for example distorted images, hallucinations, painful eye, contrast, color vision, double vision. Also, the frequency never, often etc. is very similar. Could the authors explain what the added value of the SVCq is? I agree that structured questioning of visual complaints should become routine care.

- It seems like the severity of complaints score (on a scale of 1-10) was not used in the analyses. The indications ‘never/ hardly’etc. were used to classify severity. Please explain.

- A limitation of the present study is the lack of objective data on ophthalmological disorders. Even though medical files were studied, one of the problems is that ophthalmological disorders are not recognized (and diagnosed) in PD in clinical practice (also see a recent publication of Borm et al. J Neurol 2022). So, the number of OC’s may have been underestimated. In addition, there may still have been some selection bias because only PD patients visiting the outpatient clinic of a university hospital were included. This is a selected population.

- The authors state following: “Therefore, there is a risk of underestimation in both groups. The percentage of people who indicated having visited an ophthalmologist did not differ between the groups (see Table 1). It is therefore unlikely that results were influenced by missing a large number of ophthalmic conditions in one of the groups.”

This statement confused me, since underreporting of complaints is a reason to screen for visual complaints in PD, especially regarding the results of this study with high prevalence of visual complaints in persons with PD. Then it is paradoxal to assume that persons with PD did visit the ophthalmologist with their complaints earlier. Shouldn’t persons with PD show a much higher rate of visiting an ophthalmologist? Could the authors explain this?

- I would have liked to see analyses on the different age categories. A point of discussion is whether the high number of visual complaints and disorders in PD is a consequence of the disease or related to ‘general ageing’. It would be interesting to distinguish the age categories that were matched and perform the prevalence analyses for these different age categories.

- Were co-morbidities in the PD group considered in the analyses in a way?

- In the discussion it is stated that the high prevalence of visual complaints in people with PD may negatively impact daily life. Wasn’t this also studied here? In general, I find the analyses and conclusions on the clinical impact difficult to interpret; this could be described more clearly and explicitly.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mirella Barboni

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 4;18(4):e0283122. doi: 10.1371/journal.pone.0283122.r002

Author response to Decision Letter 0


17 Nov 2022

We would like to thank the reviewers for their kind attention to our paper and their critical eye. We did our utmost to incorporate the feedback and answer the reviewers' questions as well as possible (see below). Lines mentioned refer to the document including track-changes.

Reviewer #1:

It was interesting to learn from the Authors that PD patients are at high risk of visual complaints such as trouble to reading and focusing. These alterations are likely associated, at least partially, with oculomotor impairments since other visual attributes that may be less dependent on precise fixational eye movements, such as visual field and color vision, showed much lower prevalence. […] I recommend to include in the discussion a brief description concerning the above-mentioned possible associations between visual disturbances and oculomotor alterations in PD patients that may be a subject of future investigations.

--> We added a paragraph on the possible relationship between the most common complaints and oculomotor deficits in the discussion section (lines 315-323). Furthermore, we stated that it might be interesting for future research to look into the possible relationship between visual complaints and functional disorders (lines 371-373).

Reviewer #2:

In the introduction the authors can write more about the visual defects that are reported among PD patients with relevance to their stage of PD

--> We added a paragraph discussing what was known about visual complaints from the scientific literature. We also briefly discussed the relationship to certain disease-related data, such as disease severity (lines 54-62).

Whether any subsequent ophthalmic examinations were carried out on the self-reported patients to confirm the nature of the visual condition, like assessing their visual acuity to further confirm ? unclear vision appears to be a pre-dominant complaint with 23.2% reporting, so having a simple visual acuity test on these patients would have added more value to the data.

--> We did not include assessments of visual functions. We agree that possible underlying visual function deficits might have been interesting to look into. We have recommended this for future research (lines 371-373).

The rational for focusing on complaints in the current study was supported by the following: in some cases, the target of care could be an underlying functional impairment, as for example visual acuity (suggested by the reviewer), which might be addressed by the right glasses. In others, however, underlying functional impairments, as for example oculomotor deficits, cannot be treated well, while a complaint might still be addressed in rehabilitation (e.g., by advising a certain reading distance). There may not be a one-to-one association between objectified visual impairments and subjective visual complaints. We added a few sentences on this topic in the discussion section (lines 340-348). Since the reduction of complaints is the goal of rehabilitation, and knowledge on this topic is still scarce, we chose complaints as the subject of this study.

Did the authors consider analyzing the data from PD cases based on their stage of the disease apart from classifying based on their age, if so how was the correlation between the visual condition and stages ? This would provide some insight on the ophthalmic deterioration with relevance to the severity of the PD.

--> We did take disease severity into account, by calculating differences in the presence of visual complaints between people in several disease stages, according to Hoehn & Yahr (1998; see Table 6a and 6b). These analyses indeed show that visual complaints seem to increase with disease severity. We did not perform correlations.

How the co-morbidity of diabetes among the PD cases were considered ? and does the control group contains diabetes cases ?

--> Supplementary Table 1 presents the comorbid ophthalmological conditions in both groups. We reported diabetes in case there was proven retinopathy (n = 5 in PD, n = 0 in controls). In addition, this study investigated the relationship between the presence of visual complaints and the presence of ophthalmological conditions, including retinopathy.

The authors need to clarify how many of the PD cases reported here were under dopaminergic medication and also of the total PD cases reported how many were freshly identified to have PD and without taking any dopaminergic medication ?

--> We added four rows in Table 1, describing how many people with PD were taking the most common forms of antiparkinsonian medication and how many were not taking any medication.

Also it would be nice to record the sleep patterns of the PD patients especially those undergoing dopaminergic treatment and correlate with the visual condition ?

--> We agree that this might be interesting for future research. However, we feel this is beyond the subject of the present study.

Reviewer #3:

Abstract: Please indicate the numerical prevalence in the results.

--> We included the exact prevalence of complaints in the abstract.

Introduction: The Introduction is short, I suggest a paragraph fastly citing the more important or known visual complaints. It would be informative for a general audience.

--> We added a paragraph discussing what was known about visual complaints from the scientific literature (lines 54-62).

Methods: Was there some information about the socioeconomic profile from PD patients and controls? If not, include as limitation.

--> We did not have access to information regarding the socioeconomic status of the participants. We included a statement on this in the discussion section (lines 413-416).

Results: Figure 1 has no legend in the Y- and X- axis, and the numbers have low contrast. I suggest to include the legends and paint in black the numbers and letters. Why is not indicated the statistical difference?

--> We adjusted the figure based on these comments.

Discussion: The methods of data collection in PD patients and controls were different and it is an limitation of the study. The authors should discuss about it.

--> We added a paragraph on this limitation in the discussion section (lines 392-398).

Reviewer #4:

The title can be “Prevalence and …….. - Screening Visual Complaints questionnaire outcome” or "outcome of SV...Q"; instead of “Use of the Screening Visual Complaints questionnaire”.

--> We have changed the title based on the suggestion given.

Line 69, please define mild, severe, and moderate condition staging.

--> We referred to notes e-f below Table 1 for a definition (line 88). If the editor wants us to provide a complete list of conditions excluded in the control group, we are able to provide this list.

Your control group had mild PD (line 67)? How is that not affecting your comparison with those having PD?

--> The control group had no PD; we made this more specific in the manuscript (lines 85-86).

“Dutch-speaking people were invited” implies they can be of any ethnicity speaking dutch. Is ethnicity a factor affecting PD? (DOI: 10.3233/JPD-191763)

--> It is true that people in either group could be of any ethnicity, as long as they speak Dutch. We did not collect data on ethnicity, so we cannot draw conclusion regarding its relationship with visual complaints in PD. We included a statement on this in the discussion section (lines 413-416).

Are your study participants “people” or are they “patients” of the center?

--> The people with PD were seen for their disease (i.e., as “patients”) at the Parkinson Expertise Center. In accordance with APA 7th (https://apastyle.apa.org/style-grammar-guidelines/bias-free-language/disability), we do not define these people solely by their disease, which is why we use the term “people with PD”.

Line 154, mentioning Evdk as a research assistant is unnecessary. “Two researchers” is enough.

--> We removed initials from this sentence (lines 176-177).

The authors themselves published a systematic review of “Self-reported visual complaints in PD” in 2022 (DOI: 10.3233/JPD-202324). Moreover, the svc questionnaire you have used is an existing one (with a similar sample size and control group DOI: 10.1371/journal.pone.0272559), used previously and the results are in the systematic review itself. Please explain in detail the need for this study and what additional this study is achieving, that others could not before using the same questionnaire. Basically, how did you overcome the limitations of previous studies (if any).

--> The results of the study using the SVCq (2022) are not included in the systematic review mentioned, as the review included studies that were published up to February 5, 2021. Furthermore, the previous study using the SVCq had a different purpose, which was to validate the questionnaire and examine the factor structure of the questionnaire in a sample of people with PD, rather than to investigate the prevalence and nature of visual complaints in this sample, as is the case in the present article. The main advantages of the current study is that it investigated a wide variety of function and activity related visual complaints in a large cohort of people with PD, and compared their results to an age-matched control group. As was found by the review mentioned, only few studies have previously aimed for mapping the prevalence of a number of visual complaints in people with PD. Previous studies have mainly used small sample sizes to draw conclusions on only one or a few complaints, sometimes even without comparing it to controls. These are important limitations that are overcome in this study.

Line 84-85, “In addition, a clear and clinically relevant factor structure has been demonstrated in people with PD” is unclear, please restructure.

--> We have added a sentence to clarify the meaning of this factor structure (lines 103-105).

Although PD patients were previously diagnosed and taken from medical files, please explain the diagnostic criteria of PD and staging and also for the control group.

--> Diagnosis of PD was done based on the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria. We added this in the manuscript (lines 84-85). Staging of the disease was reported in Table 1, by means of the commonly used staging by Hoehn & Yahr (1998). The control group consisted of a community sample without PD. Therefore, reporting of diagnostic criteria or disease stage is not applicable.

Please explain in detail the ophthalmological examination conducted on the PD and control group.

--> We did not perform any ophthalmological assessments. Data on any present ophthalmological comorbidities were recorded from medical files in those with PD, and in those without PD (controls) this was based on self-report (see Supplementary Table 1). This procedure was explained in the manuscript (subheading ‘Determining the presence of ophthalmological conditions’, lines 148-155).

Including people both with and without cataract surgery in the PD and control group, are you introducing any kind of bias or not? (Although you have mentioned excluding them did not alter the results). Please discuss this.

--> We explained this more clearly in the manuscript (lines 154-155). We cannot conclude that cataract surgery relieved all complaints, given the possibility of residual long-term effects or secondary cataracts. Therefore, we considered those who underwent surgery to have an OC. Since there was no difference in results after excluding people who had undergone cataract extraction, we do not expect bias of any kind.

Conclusion: “Since visual complaints can have a vast impact on the daily lives of people with PD” Have you tested the QOL in people with PD in this study? Either add a reference or remove the line.

--> This quote refers to the impact of visual complaints on the daily lives of people with PD, which we investigated through the present study (impact on daily life score, 0 - 10 scale). There is no mention of QOL in the cited quote from the conclusion.

Tables 7 and 8 look unnecessary. Adding results is enough.

--> Since reviewer #5 argues these tables contain information not previously studied and reported, we left these tables included in the manuscript.

Reviewer #5:

First, I think both the introduction and discussion need some work. It is clear that this is an underrecognized topic and in need of more study. However, I think that these sections lack a good representation of the work that has already been performed on this subject. The introduction should, in addition, also indicate what this study adds to the current literature.

--> We added a paragraph in the introduction discussing what was known about visual complaints from the scientific literature and what the current study adds to this (lines 54-62 and 70-80). In the discussion section, we also made more links between our results and previous studies (e.g., lines 299-304 and 315-323).

What is truly new (in my opinion tables 5-8) and how could this help to improve health care? Do we need screening by the ophthalmologist based on this study? And on which ophthalmological diseases? It is difficult to treat only complaints without knowing what the underlying disorders might be.

--> In particular, screening for a wide range of function and activity related visual complaints in a large group of people with PD is something that has not been done. The use of the SVCq allows for screening for isolated complaints focused on both functions and activities, which provides clear goals for care and rehabilitation. We made the added value of this study more clear (e.g., lines 70-80). As this study also shows, visual complaints are not fully explained by ophthalmological conditions. Complaints may also be present in their absence. In case complaints are present, screening for ophthalmological conditions or functional deficits can be done. However, even in the absence of these deficits, visual rehabilitation can be applied to relieve complaints (e.g., by providing aids or advice for activities that a person has difficulty with). We explained this in more detail in the discussion section (lines 340-348). In general, the current study advocates that regular screening for visual complaints is needed so that they are recognized and people can receive the right advice and rehabilitation, regardless of the cause.

It is stated in the discussion that some complaints (most seen in PD) are possible PD pathology related. This is interesting however there is no explanation on this topic.

--> There is a short explanation on this in lines 327-330. We state that for example PD related disturbances in retinal, cortical or thalamic functioning might contribute to the experience of visual complaints (supported by DOI: 10.1093/brain/aww175). In addition, we showed that complaints increase with disease progression.

In the discussion section, also a more in-depth discussion of the causes and consequences of the findings and a comparison with previous studies should be made. Now only the rationale that screening is important because of a high prevalence and a potential impact on daily life, is repeated several times in both the introduction and discussion.

--> We complemented the discussion with more links between our results and previous studies. In addition, we focused more on possible causes and consequences of our findings (e.g., lines 299-304, 315-323, and 340-348).

The SVCq is introduced as a questionnaire that screens for visual complaints in people with neurodegenerative diseases. However, the questionnaire was validated in people without neurological conditions. Please explain.

--> Even though developed to screen for visual complaints in people with neurodegenerative disorders, the items in the SVCq are general formulations of visual complaints that anyone can experience, not just people with a neurodegenerative disorder. As a first step, the SVCq was examined in a group of people without these disorders. Subsequently, we tested the found structure of the questionnaire in people with PD. Here we found similar results and clinical merit for use of the SVCq in people with PD (DOI: 10.1371/journal.pone.0272559). This is also explained in lines 102-105.

How was the question on dry eyes established? Dry eyes syndrome is a diagnosis and not typically a visual complain. Dry eyes could lead to symptoms of paradoxically to watery/teary eyes, burning/sandy/itchy eyes and/or blurred vision.

--> All items in the questionnaire were established based on literature (in which “dry eyes” were also regularly questioned; DOI: 10.3233/JPD-202324), expert opinions (e.g., neurologists and ophthalmologists working with neurodegenerative disorders, including PD), and experiences of people with a neurodegenerative disorder, including PD. A detailed description of the questionnaire development can be viewed at DOI: 10.1371/journal.pone.0232232.

The conclusion drawn in the discussion that the SVCq is very different from other questionnaires such as the VFQ-25 and the VIPD-questionnaire is not clear to me. When compared especially the VIPD-Q and the SVCq many questions are similar, for example distorted images, hallucinations, painful eye, contrast, color vision, double vision. Also, the frequency never, often etc. is very similar. Could the authors explain what the added value of the SVCq is? I agree that structured questioning of visual complaints should become routine care.

--> We tried to clarify this more in the discussion (lines 362-373). Despite several complaints appearing in both questionnaires, the VIPD-Q aims to detect underlying ophthalmological conditions. Questions are therefore for example phrased more specifically (e.g., does a complaint occur in a specific situation?). The SVCq asks about isolated complaints, at both a functional and activity level. As we found that complaints do not always directly relate to ophthalmological conditions, the aim of the SVCq is not to detect these conditions, but to guide care and rehabilitation.

It seems like the severity of complaints score (on a scale of 1-10) was not used in the analyses. The indications ‘never/ hardly’etc. were used to classify severity. Please explain.

--> We used this score as the ‘impact on daily life score’. Throughout the manuscript, we indicated more clearly where this score was used, by mentioning the 0 - 10 scale.

A limitation of the present study is the lack of objective data on ophthalmological disorders. Even though medical files were studied, one of the problems is that ophthalmological disorders are not recognized (and diagnosed) in PD in clinical practice (also see a recent publication of Borm et al. J Neurol 2022). So, the number of OC’s may have been underestimated. In addition, there may still have been some selection bias because only PD patients visiting the outpatient clinic of a university hospital were included. This is a selected population.

--> We agree that these are possible limitations of the study, which we addressed in the discussion section (lines 387-391 and 399-403).

The authors state following: “Therefore, there is a risk of underestimation in both groups. The percentage of people who indicated having visited an ophthalmologist did not differ between the groups (see Table 1). It is therefore unlikely that results were influenced by missing a large number of ophthalmic conditions in one of the groups.” This statement confused me, since underreporting of complaints is a reason to screen for visual complaints in PD, especially regarding the results of this study with high prevalence of visual complaints in persons with PD. Then it is paradoxal to assume that persons with PD did visit the ophthalmologist with their complaints earlier. Shouldn’t persons with PD show a much higher rate of visiting an ophthalmologist? Could the authors explain this?

--> Thank you for pointing this out. It is indeed incorrect what was stated here. We chose to omit the last two sentences, but to leave the limitation about the possible underestimation of the number of ophthalmic conditions (lines 399-405).

I would have liked to see analyses on the different age categories. A point of discussion is whether the high number of visual complaints and disorders in PD is a consequence of the disease or related to ‘general ageing’. It would be interesting to distinguish the age categories that were matched and perform the prevalence analyses for these different age categories.

--> In this study, we determined a positive correlation between the presence of visual complaints and age. We have also shown that people with PD experienced more visual complaints than controls. Given that these controls were age-matched to the group of people with PD, it can be concluded that the high prevalence of visual complaints in people with PD cannot be fully explained by ageing. We do agree that analyzing each age category may provide even more insight into possible interaction effects. As we already performed many analyses in this study, all of which include important variables, we do not feel that adding another set of analyses on just one of those variables is justified. Nonetheless, if the editor wants us to add these analyses, we can do that.

Were co-morbidities in the PD group considered in the analyses in a way?

--> We did not correct for comorbidities other than ophthalmological conditions. For this reason, there is a paragraph on the possible effect of this decision in the discussion section (lines 406-412).

In the discussion it is stated that the high prevalence of visual complaints in people with PD may negatively impact daily life. Wasn’t this also studied here? In general, I find the analyses and conclusions on the clinical impact difficult to interpret; this could be described more clearly and explicitly.

--> This was studied indeed, by the ‘impact on daily life score’ (0-10). Conclusions regarding impact on daily life were based on this score. We indicated more clearly where this score was used throughout the manuscript, facilitating interpretation.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Thiago P Fernandes

5 Dec 2022

PONE-D-22-24932R1Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Outcome of the Screening Visual Complaints questionnairePLOS ONE

Dear Dr. van der Lijn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for submitting your valuable work.

The reviews, which are insightful and interesting, pointed to some unexplained aspects and the authors were able to clarify them.

By my own reading, the manuscript still needs a bit of refinement, mostly related to generalisation, conciseness and the control of confounding factors. Although this may sound counterintuitive, I am keen to understand authors' claims and keen on reading a refined manuscript.

Briefly, as raised by one of the reviewers, you cannot just make too much speculation of your findings.

As we have observed through this time, PD's ocular manifestations are measured by the use of behavioural and physiological techniques. For example, we have noted that the dopamine depletion can affect eye's structure but also functional aspects from the retina to brain (based on ERPs, colour or chromatic discrimination etc.) This is not the focus of the manuscript, indeed, but those findings showed that other measures are reliable enough to detect ocular and visual manifestations, but also help, somehow, during the course of the disease. My concern here is: you are using a self-reported measure to characterise visual complains and, hence, because of that, you cannot just speculate that much with strong statements or even with some assertions. I think the authors can work on a little bit, refining the manuscript to ensure that readers and researchers can easily understand that your claims and assertions are tightened up to your results - without too much "physiology" or "all or nothing" claims.

You will notice that reviewers provided frank and clear comments and, in this round, they almost had no concerns. This is a good point, actually, and the authors can rest assure that this will be considered. However, more important is to provide a frank, clear and transparent perspective of your findings. I'd highly recommend the authors to rethink some statements where sound like "causal" relation of the self-related and visual complains - that should be interpreted as self-reported.

For example, one could say that he/she has no visual complain. But when comes to the physiological aspect, them could have cortical or subcortical damages. Well, by self-report them reported nothing, but physiologically, them have.

So basically I am gentle asking you to be cautious in this aspect and also refine your limitations pointing this difference of self-reported and other measures that really can show causal relation of the complains. Your study has merits and should be considered, but, considering these aspects, please opt to use a more conservative approach for debating your data and for your conclusions.

Overall, the manuscript reads better and has been really refined considering all of the reviewers’ comment. Also I commend the authors for their politeness and efforts. Wishing you success with the study and a very good refined version, so then we can proceed.

Please submit your revised manuscript by Jan 19 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Thiago Fernandes, MA, EbS, Sp. Neuro, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please read my comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

Reviewer #4: All comments have been addressed

Reviewer #5: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The discussion regarding the effects of abnormal eye movements on visual functions in PD has been added by the Authors. Thank you!

Reviewer #3: Dear Editor, all my issues were addressed and I considered that the manuscript is suitable to be published

Reviewer #4: (No Response)

Reviewer #5: I would like to thank the authors for addressing all comments of 5 reviewers. Most of my addressed points have been clarified.

Although, I still have concerns about the final conclusion that there are complaints without underlying OC.

In my opinion it is not possible to state this as part of the end conclusion without thorough ophthalmological assessment.

for example impaired color vison could be related to retinal dysfunction this is an OC (due to parkinson's or not) the same for dry eyes, blurred vision due to refractive errors and reading problems due to oculomotor problems or visual field deficitis.

Of course sometimes you don't know what the underlying cause to symptoms is and one can speculate it is parkinson's, but to state this with only self-reported OCs is difficult to accept for me. Especially noticing that PD patients underreport symptoms and therefore not go to eye care as often as they should.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mirella Barboni

Reviewer #3: Yes: Givago da Silva Souza

Reviewer #4: Yes: Sayantan Biswas

Reviewer #5: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 4;18(4):e0283122. doi: 10.1371/journal.pone.0283122.r004

Author response to Decision Letter 1


10 Jan 2023

(lines mentioned refer to the document including track-changes)

Reviewer #1:

The discussion regarding the effects of abnormal eye movements on visual functions in PD has been added by the Authors. Thank you!

--> We are pleased that our addition is sufficient. Thank you for the feedback.

Reviewer #3:

Dear Editor, all my issues were addressed and I considered that the manuscript is suitable to be published

--> Thank you for the compliment.

Reviewer #5:

I would like to thank the authors for addressing all comments of 5 reviewers. Most of my addressed points have been clarified. Although, I still have concerns about the final conclusion that there are complaints without underlying OC. In my opinion it is not possible to state this as part of the end conclusion without thorough ophthalmological assessment. for example impaired color vison could be related to retinal dysfunction this is an OC (due to parkinson's or not) the same for dry eyes, blurred vision due to refractive errors and reading problems due to oculomotor problems or visual field deficitis. Of course sometimes you don't know what the underlying cause to symptoms is and one can speculate it is parkinson's, but to state this with only self-reported OCs is difficult to accept for me. Especially noticing that PD patients underreport symptoms and therefore not go to eye care as often as they should.

--> We removed the conclusion on ophthalmological conditions from the abstract and conclusion, as this was not the main aim of our study, and we agree that these conditions were not extensively examined in our study as we used retrospective medical file investigation and self-report (lines 23-39, 425). Since we removed these results from the abstract, we elaborated a bit more on results related to our research questions on the prevalence and nature of visual complaints in people with Parkinson’s disease.

Furthermore, we chose to discuss the possible underestimation of ophthalmological conditions earlier in the discussion section, to enable readers to interpret the results in view of this information. We also emphasized that conclusions regarding analyses with ophthalmological conditions should be made with caution (lines 313-318).

In addition, we replaced ‘ophthalmological conditions’ with ‘identified ophthalmological conditions’ in the discussion section to indicate that we are referring only to what is known to us from medical files and self-reported information. With this, we make it even more clear that we cannot state with certainty that no other conditions were present (lines 310-312, 378).

Editor:

Thank you for submitting your valuable work.

The reviews, which are insightful and interesting, pointed to some unexplained aspects and the authors were able to clarify them.

By my own reading, the manuscript still needs a bit of refinement, mostly related to generalisation, conciseness and the control of confounding factors. Although this may sound counterintuitive, I am keen to understand authors' claims and keen on reading a refined manuscript.

Briefly, as raised by one of the reviewers, you cannot just make too much speculation of your findings.

As we have observed through this time, PD's ocular manifestations are measured by the use of behavioural and physiological techniques. For example, we have noted that the dopamine depletion can affect eye's structure but also functional aspects from the retina to brain (based on ERPs, colour or chromatic discrimination etc.) This is not the focus of the manuscript, indeed, but those findings showed that other measures are reliable enough to detect ocular and visual manifestations, but also help, somehow, during the course of the disease. My concern here is: you are using a self-reported measure to characterise visual complains and, hence, because of that, you cannot just speculate that much with strong statements or even with some assertions. I think the authors can work on a little bit, refining the manuscript to ensure that readers and researchers can easily understand that your claims and assertions are tightened up to your results - without too much "physiology" or "all or nothing" claims.

You will notice that reviewers provided frank and clear comments and, in this round, they almost had no concerns. This is a good point, actually, and the authors can rest assure that this will be considered. However, more important is to provide a frank, clear and transparent perspective of your findings. I'd highly recommend the authors to rethink some statements where sound like "causal" relation of the self-related and visual complains - that should be interpreted as self-reported.

For example, one could say that he/she has no visual complain. But when comes to the physiological aspect, them could have cortical or subcortical damages. Well, by self-report them reported nothing, but physiologically, them have.

So basically I am gentle asking you to be cautious in this aspect and also refine your limitations pointing this difference of self-reported and other measures that really can show causal relation of the complains. Your study has merits and should be considered, but, considering these aspects, please opt to use a more conservative approach for debating your data and for your conclusions.

Overall, the manuscript reads better and has been really refined considering all of the reviewers’ comment. Also I commend the authors for their politeness and efforts. Wishing you success with the study and a very good refined version, so then we can proceed.

--> Thank you for your compliments and feedback. We agree that in a previous version we drew some conclusions that were too strongly formulated. We may have speculated too much, and it was not always clear which results were found in our study and which in previous studies. Also, we may have unintentionally suggested some causal relationships. To correct this, we changed the following (in addition to what was mentioned above in the response to reviewer #5):

- We nuanced statements on complaints being present without ophthalmological conditions, by emphasizing that it is possible that complaints are related to ophthalmological conditions, as this is also suggested by results of our study. As our results raise the possibility that complaints may be present when there is no identified ophthalmological condition, we emphasize that screening for visual complaints is important in conjunction to screening for ophthalmological conditions or functional disorders (lines 375-379).

- We replaced the words "explained" or “contributed to” with "related to" or “associated with”, to indicate that we did not demonstrate any causal relationships with our study (lines 309-337).

- We made it more clear that we did not investigate any other factors besides ophthalmological conditions that may relate to experiencing visual complaints. We raised this as a possible topic for follow-up studies (lines 310-339).

- We described more clearly which results emerged from our study and which from previous studies (lines 310-339).

- We nuanced statements and conclusions and very tentatively suggest what our study can contribute to the management of visual problems in clinical practice (lines 346-355).

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 2

Thiago P Fernandes

12 Jan 2023

PONE-D-22-24932R2Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Outcome of the Screening Visual Complaints questionnairePLOS ONE

Dear Dr. van der Lijn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Thank you for addressing all comments. As mentioned before, these (10.1371/journal.pone.0272559 & https://doi.org/10.1371/journal.pone.0232232) are studies that could be considered as potential overlapping. I ask the authors to detail in the main text the main differences - with specific details re. the three studies. Also, I request the authors to disclose in a diffrent section of the file, next to the diclosures and/or conflict. 

Please submit your revised manuscript by Feb 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Thiago P. Fernandes, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 4;18(4):e0283122. doi: 10.1371/journal.pone.0283122.r006

Author response to Decision Letter 2


13 Jan 2023

(lines mentioned refer to the document including track-changes)

Editor:

As mentioned before, these (10.1371/journal.pone.0272559 & https://doi.org/10.1371/journal.pone.0232232) are studies that could be considered as potential overlapping. I ask the authors to detail in the main text the main differences - with specific details re. the three studies. Also, I request the authors to disclose in a diffrent section of the file, next to the diclosures and/or conflict.

--> We agree that it may not have been clear throughout the manuscript that similar datasets have been used previously to answer different research questions. For transparency reasons, we have revised our manuscript, and we hope the revisions clarify that previous studies focused on validating the questionnaire, whereas the current study aims to examine the prevalence of visual complaints in people with Parkinson's disease versus controls, based on the validated questionnaire, but using data from the same samples.

We adjusted the following:

- We cited both previous studies in the introduction, describing what the goals of those studies were as well as the goals of the current study, which do not overlap (lines 72-79).

- We are transparent about including the same samples in the current study and added a reference to previous studies on any occasion we discuss the samples. However, if you think we are now overdoing the number of references (self-citation), please let us know.

- We added a disclosure to the manuscript stating that data from the samples was published previously.

We would also like to mention that results of the previous studies were summarized in the method section (subheading ‘Screening Visual Complaints questionnaire’; lines 103-108) and results presented in this study have not been published elsewhere.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 3

Thiago P Fernandes

16 Jan 2023

PONE-D-22-24932R3Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Outcome of the Screening Visual Complaints questionnairePLOS ONE

Dear Dr. van der Lijn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I would like to thank you for the edits. To ensure adherence to PLOS policies concerning related studies / overlapping, I’d like to call out authors’ attention to a few another aspects. As observed in the main guidelines (https://journals.plos.org/plosone/s/ethical-publishing-practice#loc-submission-and-publication-of-related-studies), the authors will find:

“If related content is found to be too similar to the PLOS submission, or if a duplicate submission is discovered, we will reject the manuscript.

Duplicate content discovered after publication will be addressed depending on the degree of overlap. The journal may issue a correction or a retraction as appropriate.”

My concern is because you are pointing out that this study has findings on the same sample (PD’s) and the other was a validation (using the same sample). But you may think that others can say that your validation on the sample could be also interpreted as visual complaints. I understand the reasons underlying this, but also understand why to conduct another study, that’s why I think that a few things can be addressed before I continue with your study. I highly recommend the authors to address them (as also informed by the Staff), and my apologies for another round:

  1. Please extend your sample – this will help bring the novel aspects idea. I assume the authors have a few more subjects on any database?

  2. Please work on your Title and Methods to make clear: (i) studies won’t be considered as related or overlapped and (ii) your Methods should not be the same as your previous study, so you can link without repetition of the same words or write another

Please submit your revised manuscript by Mar 02 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Thiago Fernandes

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 4;18(4):e0283122. doi: 10.1371/journal.pone.0283122.r008

Author response to Decision Letter 3


1 Mar 2023

Dear Dr. Thiago Fernandes,

Enclosed you will find our response to your comments. The most important point we address here is that this paper and the previously published paper on the factor structure of the Screening Visual Complaints questionnaire (SVCq) in PLOS ONE have completely different and equally relevant aims, and perform different analyses, using the same dataset.

As indicated at the time of initial submission, data used in the current manuscript were previously used for a publication on the construct validity of the SVCq (see doi.org/10.1371/journal.pone.0272559). The current paper builds on the previous one and has used the SVCq to analyse the prevalence of visual complaints in a well-defined PD cohort. Hence, we consider our previous publication as an essential first step, before we could conduct the current analyses on the prevalence of visual complaints. We followed a similar path with our research in people with multiple sclerosis (MS). The first paper was also on the construct validity of the SVCq in people with MS, whereas the second paper published the actual prevalence of visual complaints in people with MS using this SVCq (see doi.org/10.1186/s41687-022-00443-0 and doi.org/10.1016/j.msard.2021.103429). We would like to stress that that dividing these topics over two publications should not be considered “salami slicing”. The tables in the current publication report prevalence figures, whereas our previous publication is discussing which structure of the SVCq would provide the most differentiated and solid outcomes of this scale.

Since part of your concerns refer to the re-use of data, we would like to address that according to the international guidelines for scientific journals, editors and researchers, the use of previously published data for a new publication is accepted under the following circumstances:

- it should be clear that the dataset has been previously published and reference is made to that previous publication through citations.

- the same dataset is used to answer different research questions.

- research questions are answered with a different statistical method.

- the same dependent and independent variables are used, both in number and in denomination.

- the results and conclusions clearly complement the previous publication.

Following the above-mentioned international guidelines, we now have clearly indicated that we used the same dataset as our previous PLOS ONE publication, but different parts (subscores) of it, to answer different and complementing research questions (see our Introduction lines 76-83 and Methods section lines 87-88; changes mentioned in this letter refer to the document including track-changes) and results (see Discussion lines 365-371). The main components of the studies are essentially different: the previous study performed a factor analysis on data from people with Parkinson's disease, whereas the current study calculates frequencies of visual complaints in people with Parkinson's disease, compared to controls. We now added in the Method section that analyses and results of the five subscales can be found in our previous PloS One publication (line 199), clarifying what new information the current paper adds to the previous. More importantly, the prevalence of individual visual complaints covered by the SVCq has not been previously published, thus making all results in the current manuscript new.

Although we appreciate your suggestion to add new data to the current dataset, we do not think this is a good idea. First, adding new data to an existing dataset that has been used for a previous publication could be regarded as augmenting a dataset to mask overlap. The new (augmented) dataset and the previously used dataset would still have the same amount of overlap, albeit a slightly smaller proportion of overlap. Second, the risk that readers and researchers might consider the two datasets to be different is present, and consequently both datasets might be included in a meta-analysis, which would be wrong. A more practical reason is that obtaining new ethical approval, approaching and selecting new participants with Parkinson’s disease from the same population in the North of the Netherlands would take at least a year.

We regret that we cannot fulfill all of your requests, but we hope that with the changes we have made clear that this paper answers new relevant research questions and is truly an original analysis of a known dataset.

Sincerely yours,

On behalf of Prof. Teus van Laar and Prof. Joost Heutink,

Iris van der Lijn, MSc, PhD candidate

Royal Dutch Visio & University of Groningen

Department of Clinical and Developmental Neuropsychology

Grote Kruisstraat 2/1

9712 TS Groningen

The Netherlands

+316-36319906

i.van.der.lijn@rug.nl

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 4

Thiago P Fernandes

3 Mar 2023

Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Outcome of the Screening Visual Complaints questionnaire

PONE-D-22-24932R4

Dear Dr. van der Lijn,

Thank you for your prompt replies. First, I completely understand authors’ claim – and am not arguing this since these are good points. I called out authors’ attention due to PLOS policies (which I have been informed twice). While I think this is crystal clear, and am proceeding with your study, I just ask in a more friendly way to check again possibility of overlapping in future works using any kind of tool. My “advice” is just some systems will automatically say “no, this is overlapping, do not proceed” and will not let the authors’ explain. As I am sure you are aware of this, just think that my “advice” is because we all went through this kind of situation.

Apart from it, thank you for your explanations & importantly re. the strategy I thought was interesting (add more data). A few times you can bear with this request by others, but I have not seen any issue & think the reply was interesting.

Overall, if there is still any concern or thing remaining, PLOS will contact the authors directly. I am wishing you success with your application (am seeing you are PhD candidate) but also wishing success with your very good study.

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Thiago Fernandes, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for your prompt replies. First, I completely understand authors’ claim – and am not arguing this since these are good points. I called out authors’ attention due to PLOS policies (which I have been informed twice). While I think this is crystal clear, and am proceeding with your study, I just ask in a more friendly way to check again possibility of overlapping in future works using any kind of tool. My “advice” is just some systems will automatically say “no, this is overlapping, do not proceed” and will not let the authors’ explain. As I am sure you are aware of this, just think that my “advice” is because we all went through this kind of situation.

Apart from it, thank you for your explanations & importantly re. the strategy I thought was interesting (add more data). A few times you can bear with this request by others, but I have not seen any issue & think the reply was interesting.

Overall, if there is still any concern or thing remaining, PLOS will contact the authors directly. I am wishing you success with your application (am seeing you are PhD candidate) but also wishing success with your very good study.

Reviewers' comments:

Acceptance letter

Thiago P Fernandes

27 Mar 2023

PONE-D-22-24932R4

Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease - Outcome of the Screening Visual Complaints questionnaire

Dear Dr. van der Lijn:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Thiago P. Fernandes

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Ophthalmological conditions in people with PD and age-matched control.

    (PDF)

    S2 Table. Screening visual complaints questionnaire–Dutch version.

    (PDF)

    S3 Table. Screening visual complaints questionnaire–English version.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The data that support the findings of this study are available from DataverseNL. Because of ethical reasons, restrictions apply to the availability of these data (i.e., the combination of variables can potentially lead to participants being identified). Data are available at https://doi.org/10.34894/ODVGUV with the permission of the ethics board of the Faculty of Behavioral and Social Sciences, University of Groningen (contact: dcc@rug.nl).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES